Vibrio vulnificus is an estuarine, gram-negative bacterial pathogen belonging to the family Vibrionaceae. Unlike V. cholerae O1, V. vulnificus is encapsulated and invasive and causes fulminant primary septicemia and necrotizing wound infections in addition to gastroenteritis in humans (21) . V. vulnificus specially affects subjects with liver disease, long-term alcohol abuse, diabetes mellitus, hemochromatosis, gastrointestinal disorders, and immunosuppression resulting from corticosteroid therapy, cancer, and AIDS (12, 14, 15, 32, 35) . V. vulnificus infections have been reported in a subject with AIDS-related complex (3) and less frequently in apparently healthy subjects as well (14, 25) . Infection is associated with consumption by susceptible hosts of raw shellfish containing the bacteria, especially oysters, or by contamination of preexisting wounds with seawater (21) . The annual incidence of symptomatic V. vulnificus infection in U.S. coastal areas (Atlantic and Gulf coasts) approximates 0.6 per 100,000 (10, 12, 14) . Cases have been reported not only from the United States but also from Korea, Japan, and Taiwan (4, 13, 23, 32) .
Subjects with V. vulnificus septicemia often have a rapidly progressive, fulminant course (12, 14, 32) , despite aggressive antimicrobial therapy and supportive care. Primary septicemia due to V. vulnificus is manifested by acute onset of fever and decreased blood pressure. Skin lesions, typically bullae, develop in more than half of patients with septicemia (12, 14, 23) .
Fifty percent of patients with wound infections require surgical debridement or amputation (36) . The mortality rate ranges from 55 to 79% and exceeds 90% for patients who become hypotensive within the first 24 h of hospitalization. In a summary of data from Florida cases (14) , the mean time from hospital admission to death was 2 days. Subjects who survive frequently have long-term complications associated with multiple organ system failure and prolonged stays in intensive care units. Before culture results become available, it is often possible to make a presumptive diagnosis of V. vulnificus septicemia in a high-risk patient on the basis of the clinical presentation (hypotension and bullous skin lesions) and an appropriate epidemiologic history, i.e., consumption of raw oysters and exposure of a wound to seawater.
Several potential virulence determinants such as the V. vulnificus capsular polysaccharide (VvPS), a cytolytic hemolysin, an elastolytic protease, and the lipopolysaccharide are believed to play a role in pathogenesis (1, 8, 16, 31) . Previous studies by us and other groups have established the critical role of VvPS in virulence and the less important role of cytolysin or elastase in pathogenesis (6, 18, 22, 37, 38) . VvPS is known to confer resistance to phagocytosis (11, 17, 39) and to complement-mediated serum bacteriolysis (2, 11, 29) . VvPS occurs in multiple carbotypes. Previously, we have identified 10 carbotypes in a limited number of clinical isolates obtained from different parts of the United States (9) .
The high mortality, the severity of infections, and the rapidity with which septicemic patients die suggest the utility for vaccines or vaccine-derived prophylactic and therapeutic regi-mens against V. vulnificus. We recently synthesized various prototype conjugate vaccines of V. vulnificus composed of carbotype 1 VvPS covalently coupled to homologous cytolysin or elastase or to tetanus toxoid (TT), using two different synthetic schemes (6) . The conjugate vaccines prepared following the carboxyl activation of the VvPS produced elevated capsularspecific antibodies and conferred 80% protection to actively immunized mice. In contrast, mice immunized with the unconjugated, T-cell-independent formulation of VvPS showed low levels of antibodies and 100% mortality (6), indicating its limitation as a potential vaccine candidate. Cytolysin and elastase alone were not effective in protection.
The clinical management of V. vulnificus septicemia and wound infections involves appropriate antibiotic therapy and, in wound infections, removal of necrotic tissues. Passive immunization with hyperimmune globulins to capsular polysaccharides has been successfully used in the treatment of systemic infections caused by Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitidis (24, 30) . Passive administration of antibodies is a potential adjunctive therapeutic option for the prophylaxis and treatment of V. vulnificus septicemia. In this report, we describe studies performed to evaluate the ability of V. vulnificus conjugate-induced hightitered antisera to confer passive protection in a murine model. The efficacies of VvPS conjugate-induced antisera were evaluated in mice when administered both before and after lethal challenge.
Carbotypes 1 and 2 of V. vulnificus account for about onethird of clinical isolates and share the disaccharide unit, ␣-2-acetamido-2,6-dideoxyglucopyranose and ␣-2-acetamido-2,6-dideoxygalactouronic acid (26, 27) . The repeat unit of carbotype 2 VvPS has two additional sugar residues, ␣-2-acetamido-2,6-dideoxygalactopyranose and ␣-2-acetamido-2,6-dideoxymannopyranose (27) . Because of this partial antigenic similarity and the reported weak serological cross-reaction between carbotype 1 and 2 VvPS (9, 27), we were also interested in evaluating the capacity of carbotype 1 VvPS conjugateinduced antisera to cross-protect against a lethal challenge with carbotype 2 V. vulnificus in mice. Effects of the Ribi adjuvant on the immunogenic potency of various VvPS conjugate vaccines were also evaluated.
MATERIALS AND METHODS
Bacterial strains. Opaque and encapsulated variants of V. vulnificus carbotypes 1 (strain MO6-24/O) and 2 (strain BO62316) were used in mouse protection studies and as sources of VvPS (9) . Both strains were originally isolated from the blood of patients with septicemia and were stored at Ϫ70ЊC in Luria (L) broth containing 50% glycerol.
Mice. Five-to six-week-old, female, outbred Swiss albino mice purchased from Charles River Breeding Laboratories, Inc., Wilmington, Mass., were used for all experiments. The animals were rested for about a week before the experiments were performed.
VvPS. VvPS of carbotypes 1 and 2 were prepared and purified as described previously (9, 26, 27) .
Conjugate vaccines. The synthesis, characterization, and composition of various VvPS conjugate vaccines prepared by using different synthetic schemes have been described previously (6) . VvPS-TTa, VvPS-cytolysin, and VvPS-elastase were prepared by carboxyl activation of the VvPS, and VvPS-TTb was prepared by hydroxyl activation of the VvPS. All the conjugate vaccines were of carbotype 1 VvPS.
Effects of the Ribi adjuvant on VvPS conjugates. Effects of the Ribi adjuvant on the immunogenic potency of VvPS-protein conjugates were evaluated. The Ribi adjuvant consists of monophosphoryl lipid A (MPL) and trehalose dicorynomycolate (Ribi ImmunoChem Research, Inc., Hamilton, Mont.). Groups of mice were injected intraperitoneally (i.p.) with 5.0 g of VvPS-TTa, VvPS-TTb, VvPS-cytolysin, and VvPS-elastase conjugate vaccines admixed in 50 g of the Ribi adjuvant in saline. Mice were immunized on day 1 and boosted on day 21. Because of the availability of limited amounts of VvPS-cytolysin and VvPSelastase conjugates, only one immunization was possible with these vaccines. Mice were bled on days 21 and/or 28, and the sera were analyzed for VvPS antibodies.
Hyperimmune antisera. Hyperimmune rabbit antiserum to VvPS-TTa (enzyme-linked immunosorbent assay [ELISA] titer, 25,600) and hyperimmune murine antisera to TT were prepared by two subcutaneous or i.p. injections with Freund's complete and incomplete adjuvants as described previously (9) . Murine hyperimmune antisera to VvPS-TTa and VvPS-TTb were prepared by pooling murine sera from the experiment that used the Ribi adjuvant. Murine antibodies to an unrelated group B meningococcal polysaccharide (MenB PS) were similarly raised using a MenB PS-protein conjugate and the Ribi adjuvant (5).
Passive immunization. Two separate experimental designs were included, and all mice were immunized i.p. with VvPS-TTa-or VvPS-TTb-induced antisera. Antisera to VvPS-cytolysin and to VvPS-elastase conjugate vaccines were not used in any protection experiments.
(i) Immunoprophylactic efficacy. Experiments 1 through 4 were performed to evaluate the immunoprophylactic efficacies of VvPS-TTa-and VvPS-TTb-induced antisera against carbotype 1 and 2 V. vulnificus septicemia by immunizing mice 24 h before challenge infection. Mice tested in experiments 1 and 3 were passively immunized i.p. with 150 l of murine VvPS-TTa conjugate-induced antisera. Each experiment included three control groups of mice, which received 150 l of either saline or murine antibodies with specificity for TT or for an unrelated MenB PS. Mice tested in experiments 2 and 4 were passively immunized i.p. with murine antiserum to VvPS-TTb conjugate (150 l) and rabbit antiserum to VvPS-TTa conjugate (200 l), respectively. Control mice in these experiments received corresponding volumes of normal (nonimmune) rabbit or mouse serum. A group of eight mice was pretested for lack of serum sickness by injecting them i.p. with 200 l of normal rabbit serum and observing them for 96 h.
(ii) Immunotherapeutic efficacy. Experiments 5 and 6 were performed to evaluate the immunotherapeutic efficacy of hyperimmune sera to both VvPSTTa and VvPS-TTb conjugates against carbotype 1 V. vulnificus by treating mice with the respective antiserum 2 h after lethal bacterial challenge. Mice tested in experiments 5 and 6 were treated with 150 l of rabbit antiserum to VvPS-TTa conjugate vaccine and murine antiserum to VvPS-TTb conjugate vaccine, respectively. The control mice in both experiments received the same volume of normal, nonimmune rabbit or mouse serum.
Challenge infection of mice. Encapsulated and opaque variants of carbotype 1 or 2 V. vulnificus were harvested from a fresh L-agar plate (6) . The colonies were suspended in sterile phosphate-buffered saline (pH 7.4) and inoculated in 0.5-ml volumes. Inoculum size was estimated by measuring the optical density at 600 nm of a log-phase culture and was confirmed by duplicate plating on L agar.
The challenge infection was performed i.p. as described previously (6) . Mice in experiments 1 and 2 were challenged i.p. with ϳ15 50% lethal doses (LD 50 ) (6 ϫ 10 7 CFU) and ϳ5 LD 50 (2.1 ϫ 10 7 CFU) of carbotype 1 V. vulnificus, respectively, ϳ24 h after passive immunization. Mice in experiments 3 and 4 were challenged with ϳ1 LD 50 (1.3 ϫ 10 9 CFU) of carbotype 2 V. vulnificus ϳ24 h after passive immunization. Mice in experiments 5 and 6 and those mice that were injected with normal rabbit serum to observe for serum sickness were challenged with ϳ25 LD 50 (9.9 ϫ 10 7 CFU) of carbotype 1 V. vulnificus ϳ2 h before immunotherapeutic treatment with conjugate-induced antisera. Survival over challenge infection was chosen as the decisive criterion for protection, and mice were watched for death up to 76 h following the challenge.
Antibody analysis. A previously described ELISA was used to measure immunoglobulin G (IgG) and IgM capsular antibody levels in the individual and pooled sera. The linear dilution curves of individual murine sera were compared with the reference linear curve obtained with a pooled polyclonal murine antiserum as described previously (6); the antibody levels were expressed as ELISA units per milliliter (mean Ϯ standard error). The ability of VvPS-TTa-induced antisera to react with the carbotype 2 polysaccharide was also evaluated by ELISA (6, 9) .
VvPS IgG and IgM levels (micrograms per milliliter) in the two murine hyperimmune sera used in protection experiments were quantitated by using VvPS-specific monoclonal IgG and IgM with known concentrations of antibodies (24a) as reference standards in ELISA. The concentrations of specific antibodies in the monoclonal antibodies were quantitated with a commercial radial immunodiffusion kit (Southern Biotechnology Associates, Birmingham, Ala.).
Statistical analysis. Differences in capsular antibody levels elicited by various VvPS-protein conjugate vaccines were determined by the two-tailed Student t test. The survival rates among mice in different study groups were compared by chi-square test 32 h following the challenge, after which no deaths occurred.
RESULTS AND DISCUSSION
In our previous study, we studied the immunogenicity of saline formulations of VvPS-TTa, VvPS-TTb, VvPS-cytolysin, and VvPS-elastase conjugate vaccines (6). In the current study, we evaluated the immunogenic potential of these conjugate vaccines in an adjuvant formulation admixed with the Ribi adjuvant. MPL is an attenuated lipopolysaccharide derivative with immunostimulating abilities (33) . MPL has been administered to humans as a part of anticancer therapy (20) (Table 1 , experiment B). The capsular antibody levels elicited after the second immunization were significantly higher than those elicited by saline formulations of both conjugates (P Յ 0.0001 by the two-tailed Student t test). Although VvPS-cytolysin and VvPS-elastase conjugate vaccines were not available in sufficient quantities for the second immunization, the difference in IgG and IgM responses following one immunization with these conjugates was statistically significant (P Յ 0.002). Previously, the saline formulation of the VvPS-TTb conjugate (synthesized following hydroxyl activation of the VvPS) elicited a variable immune response and less optimal protection (22%) in actively immunized mice compared with three other vaccines synthesized after carboxyl activation of the VvPS (6). However, in the present study, the VvPS-TTb conjugate vaccine was better recognized by the murine system upon i.p. administration with the Ribi adjuvant and evoked a significant quantitative shift in the VvPS antibody response after two immunizations (P Ͻ 0.0001 by the two-tailed Student t test). When pooled and administered, the serum conferred 100% passive protection against a 5-LD 50 challenge with carbotype 1 V. vulnificus. The disease course of V. vulnificus septicemia in mice was noted. The i.p. administration of ϳ5 to 25 LD 50 of carbotype 1 and ϳ1 LD 50 of carbotype 2 V. vulnificus in mice resulted in a rapidly lethal septicemic infection. Within 2 h of infection, the mice manifested lethargy, ruffled fur, and ataxia. Almost all control mice died within 8 h following the infection irrespective of whether they were injected with saline or serum with specificity for an unrelated carbohydrate antigen (MenB PS) or for TT, before or after the infection. All eight mice that were observed for serum sickness after administration of nonimmune rabbit serum and then challenged with ϳ25 LD 50 of carbotype 1 V. vulnificus also succumbed to septicemia (data not shown).
The concentrations of VvPS-specific IgG and IgM in murine hyperimmune antisera to VvPS-TTa and VvPS-TTb conjugates were estimated to be 3,831 and 466 g/ml and 1,500 and 274 g/ml, respectively. Both VvPS-TTa-and VvPS-TTb-induced hyperimmune antisera, at the doses used (41.0 to 93.0 g of VvPS-specific IgM and 225 to 575 g of VvPS-specific IgG), showed the potential to prevent mice from becoming infected with the homologous carbotype and also to prevent their death after a recent lethal bacterial challenge. A virtual 100% passive protection was conferred by VvPS-TTa-and VvPS-TTb-induced antisera when given as immunoprophylactic agents 24 h before the lethal challenge (Table 3 , experiments 1 and 2); 73 to 100% mortality was observed among control mice (P Ͻ 0.001 by chi-square test). Protection conferred did not require the simultaneous injection of antibodies and bacteria. Potentially, VvPS-binding antibodies act by potentiating phagocytosis and complement-mediated bacterial killing.
More striking was the survival of infected mice that were treated with the conjugate-induced antisera after a lethal infection. When used as an immunotherapeutic regimen to treat mice with an established 2-h-old infection with ϳ25 LD 50 of carbotype 1 V. vulnificus, VvPS-TTa conjugate-induced rabbit antiserum protected 73% of lethally infected mice; 80% of control mice administered normal rabbit serum died (P ϭ 0.01). Compared with the 100% protection observed when administered as an immunoprophylactic agent against a ϳ5-LD 50 challenge, the VvPS-TTb conjugate-induced antiserum conferred a modest 60% protection when used as an immunotherapeutic regimen in mice infected with the highest infective dose of the study, i.e., ϳ25 LD 50 (Table 2 , experiment 6). However, no statistical significance (P ϭ 0.2) was achieved in the latter experiment compared with the survival rate among control mice (33%). It is most likely that an infection with a lower challenge dose would have produced a significant protective effect. Interestingly, the average survival in antibodytreated mice in experiments 5 and 6 was prolonged by 8 to 12 h (data not shown). The clinical relevance of reversal of progressive disease course and delay in death of mice following immunotherapy received after the establishment of a lethal infection (at a stage when animals were quite sick with visible signs of illness) is very promising.
The relationship between antigenic sharing, immunogenicity, and biologic activity is intriguingly complex. The reported partial structural similarity and a weak serological cross-reaction (27) between V. vulnificus carbotypes 1 and 2 prompted us to evaluate the ability of carbotype 1 conjugates to confer cross-protection against a lethal challenge with carbotype 2 V. vulnificus. At the amounts used in the current study, the i.p. administration of VvPS-TTa-induced murine or rabbit antisera 24 h before lethal challenge of mice with 1 LD 50 of carbotype 2 V. vulnificus had no protective effect on survival of mice, suggesting the lack of any such cross-protection (Table 3 , experiments 3 and 4). There was 80 to 93% mortality among passively protected mice and 70 to 93% mortality among control mice that received saline or antiserum to TT or to MenB PS. The lack of cross-protection may be due to the decreased density of protective determinants on carbotype 2 VvPS or masking of the protective epitope(s) by the extra sugars, ␣-2-acetamido-2,6-dideoxygalactopyranose and ␣-2-acetamido-2,6-dideoxymannopyranose, or may simply reflect the less than optimal quantity of antisera administered in the current study. The results suggest that experimentation using in vivo animal models is essential to correlate the biologic significance of serologic cross-reactivity between carbotypes and that serologic cross-reactivity is not a precise determinant of biological efficacy against cross-reacting carbotypes.
In conclusion, our results further support the importance of VvPS antibody-mediated protective immunity against V. vulnificus septicemia. The Ribi adjuvant significantly augmented the capsular antibody responses of four different VvPS-protein conjugate vaccines. A strong carbotype-specific passive protection was elicited in a murine model of V. vulnificus septicemia, using high-titered antisera raised in two different animal species to two VvPS-TT conjugate vaccines prepared by different synthetic schemes. The antisera conferred total protection to mice upon administration 1 day before lethal challenge infection with homologous carbotype 1 V. vulnificus. The finding that VvPS-TT-induced antiserum administered after the onset of symptoms was able to reverse the disease course and extend the life of lethally infected mice suggests a potential therapeutic role for conjugate-derived immune globulins. The multiplicity of V. vulnificus carbotypes (7, 9) will necessitate the synthesis of multivalent conjugate formulations, and further studies will be required to estimate the minimum concentration of VvPS antibodies needed to confer protection in mice. Nonetheless, our results suggest that high-titered immune globulins (derived from plasma donors immunized with a multivalent VvPS conjugate) have possible utility both in passive immunoprophylaxis of targeted populations and as an adjuvant to therapy in persons with severe V. vulnificus infections. 
